Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer - KisMET-01

NCT05652868 is registered in ClinicalTrials.gov with Mythic Therapeutics as lead sponsor.

NCT NCT05652868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05652868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer - KisMET-01
Lead sponsor
Mythic Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
March 23, 2023
Completion date
November 7, 2025
Enrollment
227 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small cell lung cancer, advanced non-small cell non-squamous lung cancer, advanced non-small cell squamous lung cancer, non-small cell lung cancer, nsclc, nsclc stage iiib, nsclc stage iv